Research and Markets (http://www.researchandmarkets.com/research/3738ca/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
This Argentina Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Argentina's pharmaceuticals and healthcare industry
The report calculates Argentina's pharmaceutical expenditure to have been ARS11.56bn (US$3.73bn) in 2008. By 2013, wthe publisher expects the total amount spent on prescription and OTC medicines to have reached a value of ARS26.62bn (US$4.23bn) equating to a compound annual growth rate of 17.8%. In US dollar terms, however, as a result of the weakening peso, drug market expenditure will fall sharply from US$3.73bn in 2008 to US$3.37bn in 2009. This will affect all the subsequent forecasts in this report. In BMI's Business Environment Rankings for Q409, Argentina is ranked in 7th place in the America's region. Globally, Argentina is ranked in 31st position, above Russia and Qatar and just behind Turkey and Colombia. Argentina is present on the Pharmaceutical Research and Manufacturers of America (PhRMA)'s Special 301 Submission (2009) Priority Watch List owing to the lack of protection of undisclosed test data and other information, in a manner that is inconsistent with its obligations under the World Trade Organization (WTO)'s Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement.